PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-3.67%
Cash & equivalents declining -3.67% while Medical - Pharmaceuticals shows -3.67% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
100.00%
Short-term investments yoy growth ≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt might see stronger near-cash accumulation as an opportunity. Check yields vs. peers.
-3.67%
Cash + STI yoy growth 0.5-0.75x the Medical - Pharmaceuticals median of -6.08%. Guy Spier would be cautious about potential underfunding of liquidity.
-39.20%
Receivables growth is below half the Medical - Pharmaceuticals median of 2.01% (much lower). Joel Greenblatt would investigate if this reflects stronger collection discipline.
-3.35%
Inventory growth less than half of Medical - Pharmaceuticals median of 3.35%. Joel Greenblatt might see well-managed stock levels if revenue is fine.
34.96%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
-2.86%
1.25-1.5x the Medical - Pharmaceuticals median of -2.50%. Mohnish Pabrai would examine if this advantage is strategic or idle cash buildup.
1.43%
PP&E growth below half of Medical - Pharmaceuticals median of 11.00%. Jim Chanos would suspect potential underinvestment or strategic shift away from core assets.
No Data
No Data available this quarter, please select a different quarter.
-5.23%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
-5.23%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see big intangible expansions as a red flag for future impairments.
18.75%
≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees a bigger push into long-term investments. Check synergy with core business.
-1530.48%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees large expansions in deferred tax assets, possibly pointing to bigger NOLs.
1045.64%
Above 1.5x Medical - Pharmaceuticals median of 0.77%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
1.28%
Below half the Medical - Pharmaceuticals median of 5.60%. Jim Chanos sees a sharp divergence from peers, possibly a sign of strategic retreat or capital shortage.
100.00%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees potential red flags in big "other" asset lumps.
0.06%
Below half the Medical - Pharmaceuticals median of 0.52%. Jim Chanos might see potential stagnation or distress vs. peers.
-0.01%
Payables growth below half of Medical - Pharmaceuticals median of 4.54%. Joel Greenblatt sees more conservative payables management vs. peers.
No Data
No Data available this quarter, please select a different quarter.
-57.91%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
-84.57%
Below half Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potential sales pipeline shortfall.
275.06%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
-2.59%
Below half Medical - Pharmaceuticals median of 0.23%. Joel Greenblatt sees more conservative short-term leverage than peers.
-5.27%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
107.55%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potentially alarming surge in other LT obligations.
-2.47%
Below half Medical - Pharmaceuticals median of 2.45%. Joel Greenblatt sees more conservative long-term liability expansion vs. peers.
No Data
No Data available this quarter, please select a different quarter.
-2.57%
Below half Medical - Pharmaceuticals median of 4.63%. Joel Greenblatt sees a much lower liability expansion vs. peers.
No Data
No Data available this quarter, please select a different quarter.
3.36%
Below half Medical - Pharmaceuticals median of -3.72%. Jim Chanos suspects poor profitability or large dividend drains.
7.78%
Near Medical - Pharmaceuticals median of 8.57%. Charlie Munger sees standard changes in intangible gains/losses.
No Data
No Data available this quarter, please select a different quarter.
3.14%
Below half Medical - Pharmaceuticals median of -1.60%. Jim Chanos suspects slower net worth growth or losses vs. peers.
0.06%
Below half Medical - Pharmaceuticals median of 0.52%. Jim Chanos suspects a major slowdown or distress.
502000.00%
≥ 1.5x Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees bigger push into investments vs. peers.
-41.08%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
-97.18%
Below half of Medical - Pharmaceuticals median 14.79%. Joel Greenblatt sees stronger deleveraging or cash accumulation vs. peers.